China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Rating Upgraded by Wall Street Zen

China SXT Pharmaceuticals (NASDAQ:SXTC) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

China SXT Pharmaceuticals Stock Performance

Shares of SXTC opened at $4.10 on Friday. The firm’s 50-day moving average price is $110.02 and its 200-day moving average price is $142.30. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a 1-year low of $3.10 and a 1-year high of $83,758.80.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, July 1st. The company reported ($5.60) earnings per share (EPS) for the quarter. The company had revenue of $0.26 million for the quarter.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in SXTC. Virtu Financial LLC grew its position in shares of China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after buying an additional 15,013 shares during the period. XTX Topco Ltd bought a new position in shares of China SXT Pharmaceuticals in the 4th quarter worth about $36,000. Finally, Citadel Advisors LLC bought a new position in shares of China SXT Pharmaceuticals in the 3rd quarter worth about $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.